EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes

Eiji Nakatani iD, Hiromitsu Ohno, Takayoshi Nagahama, Toru Tonoike, Hiromichi Yui, Tatsunori Satoh, Taku Matsunaga, Daito Funaki, Chikara Ueki, Emi Ohata, Akinori Miyakoshi, Ataru Igarashi und 4 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0336038 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Eiji Nakatani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Biguanides, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiauoka Prefecure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly recommended as first-line treatment for type 2 diabetes mellitus (T2DM), but head-to-head data comparing them with metformin, the canonical biguanide, remain sparse in Japan.

Objective

To compare the long-term effectiveness and cost of initiating treatment with a biguanide versus an SGLT2 inhibitor, excluding the alternative class for 12 months but permitting other antidiabetic drugs, on a composite of major cardio-cerebrovascular events and all-cause death, and a composite of diabetic complications.

Methods

We emulated a new-user cohort trial using the Shizuoka Kokuho Database (2014–2021). Patients initiating treatment with either a biguanide or an SGLT2 inhibitor, while avoiding the alternative class during the first 12 months but allowing other glucose-lowering agents, were included. Follow-up began at treatment initiation; those who received the comparator drug within 12 months were excluded. After 1:1 propensity-score matching on demographic, clinical, laboratory, and lifestyle variables, cause-specific Cox models estimated hazard ratios (HRs). Daily medication costs were compared.

Results

After matching, 1,246 patients (623 per group) were followed for a median of 2.9 years (maximum 7.2 years). Cardio-cerebrovascular composite: 44/623 biguanide users (7.1%) and 35/623 SGLT2 inhibitor users (5.6%) experienced a first event (HR 0.80, 95% CI 0.51–1.24). Diabetic complications: 86/623 (13.8%) vs. 78/623 (12.5%) (HR 0.88, 95% CI 0.70–1.13). Median daily drug cost was 124.7 JPY for biguanides and 184.0 JPY for SGLT2 inhibitors (P < 0.001).

Conclusion

Using a large-scale regional database from Japan, we found that among adults with type 2 diabetes without prior major cardiac or renal disease, first-line treatment with an SGLT2 inhibitor did not reduce risks of cardio-cerebrovascular events, mortality, or complications compared with metformin, and cost about 50% more.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsBiguanidesCardiovascular DiseasesDiabetic NephropathiesHypoglycemic AgentsDiabetic RetinopathyDiabetic NeuropathiesHumansMaleFemaleMiddle AgedAgedJapanMetforminCerebrovascular Disorders

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBiguanidesHypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
  • Allied Medical K.K., Tokyo, Japan.
  • Department of Biostatistics and Data Science, Graduate School of Medical Science Nagoya City University, Nagoya, Japan.
  • Institute of Humanistic Social Medicine, Tokyo, Japan.
  • Shizuoka General Hospital, Shizuoka, Japan.
  • Department of Academic Services, 4DIN Ltd., Tokyo, Japan.

ORCID-Profile: Eiji Nakatani

Förderung

  • Shiauoka Prefecure

Zitieren

APA

Nakatani, E., Ohno, H., Nagahama, T., Tonoike, T., Yui, H., Satoh, T., Matsunaga, T., Funaki, D., Ueki, C., Ohata, E., Miyakoshi, A., Igarashi, A., Tanaka, Y., Kaneda, H., Kumamaru, H., & Sugawara, A. (2025). Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes. PLOS One. https://doi.org/10.1371/journal.pone.0336038

Vancouver

Nakatani E, Ohno H, Nagahama T, Tonoike T, Yui H, Satoh T, et al. Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes. PLOS One. 2025. doi:10.1371/journal.pone.0336038

BibTeX
@article{Nakatani2025,
  author = {Nakatani, Eiji and Ohno, Hiromitsu and Nagahama, Takayoshi and Tonoike, Toru and Yui, Hiromichi and Satoh, Tatsunori and Matsunaga, Taku and Funaki, Daito and Ueki, Chikara and Ohata, Emi and Miyakoshi, Akinori and Igarashi, Ataru and Tanaka, Yoshihiro and Kaneda, Hideaki and Kumamaru, Hiraku and Sugawara, Akira},
  title = {Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0336038}
}
Kostenlos starten →